Entresto Cleared In Europe As Reimbursement Delay Stunts US Uptake
This article was originally published in Scrip
Executive Summary
Novartis AG's Entresto, which has had sluggish US sales since launch earlier this year, has been granted marketing authorization in the EU for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).